Alkermes plc shares fell 5% to $50.05 after its second-quarter 2026 report showed a 27% revenue jump to $496.0 million but GAAP net income collapsed to $0.5 million from $87.1 million a year earlier. Proprietary net sales reached $411.7 million, led by VIVITROL at $124.5 million, ARISTADA at $96.7 million, LYBALVI at $94.0 million, and newly integrated narcolepsy therapy LUMRYZ at $96.6 million, while manufacturing and royalty revenues added $79.0 million. Adjusted EBITDA grew to $139.2 million, yet integration costs and higher R&D and SG&A spending weighed on bottom-line earnings. The company also announced that CEO Richard Pops will become Executive Chairman and COO Blair Jackson will take over as CEO on August 1.
Alkermes PlcGAAP net income collapsed to $0.5M from $87.1M despite revenue surge, and shares fell 5%.
